因艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺与含钙产品之间可能存在药物相互作用导致的HIV病毒反弹：2例报告
HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases.
作者信息
Kang-Birken S Lena, El-Sayed Dena, Prichard John
机构信息
1 Immunology Clinic, Ventura County Medical Center, Ventura, CA, USA.
2 Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA.
出版信息
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821653. doi: 10.1177/2325958218821653.
Abstract
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance. We report a potential drug-drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt. Both cases resulted in rise in HIV RNA levels and emergence of M184 V mutation and resistance to elvitegravir and raltegravir. To the best of our knowledge, these 2 cases are the first reports of rapid emergence of mutation from coadministration of E/C/F/TAF and calcium.
摘要
艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺（E/C/F/TAF）是一种强效的固定剂量、每日一次的HIV-1治疗方案，耐药情况罕见。我们报告了2例同时接受HIV和脑弓形虫病治疗的女性患者中可能存在的药物相互作用：1例是E/C/F/TAF与碳酸钙之间的相互作用，另1例涉及亚叶酸钙盐。两例均导致HIV RNA水平升高，出现M184V突变，并对艾维雷韦和拉替拉韦产生耐药。据我们所知，这2例是E/C/F/TAF与钙共同给药后迅速出现突变的首例报告。
相似文献
1
HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases.因艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺与含钙产品之间可能存在药物相互作用导致的HIV病毒反弹：2例报告
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821653. doi: 10.1177/2325958218821653.
2
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.在初治的 HIV 感染青少年中，含有艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺的单片复方制剂的安全性、疗效和药代动力学：一项单臂、开放标签试验。
Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.
3
Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺用于治疗成人HIV感染。
Expert Opin Pharmacother. 2016;17(3):409-19. doi: 10.1517/14656566.2016.1129401.
4
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.在初治的HIV-1感染受试者中，使用埃替格韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺或埃替格韦/考比司他/恩曲他滨/替诺福韦酯进行96周治疗后耐药性出现频率较低。
Antivir Ther. 2017;22(5):443-446. doi: 10.3851/IMP3125. Epub 2017 Jan 11.
5
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.初治HIV-1患者接受埃替拉韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺治疗48周后罕见出现耐药性。
HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731.
6
A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.捷扶康（艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺）用于治疗HIV-1感染的疗效和安全性综述
J Pharm Pract. 2018 Apr;31(2):216-221. doi: 10.1177/0897190017710519. Epub 2017 May 30.
7
Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.替诺福韦艾拉酚胺、恩曲他滨、埃替格韦和考比司他联合疗法治疗HIV。
Expert Rev Anti Infect Ther. 2017 Mar;15(3):195-209. doi: 10.1080/14787210.2017.1286736. Epub 2017 Feb 8.
8
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.简要报告：替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯随机双盲比较，二者均与埃替格韦、考比司他和恩曲他滨联合用于初治HIV-1感染：第96周结果
J Acquir Immune Defic Syndr. 2016 May 1;72(1):58-64. doi: 10.1097/QAI.0000000000000940.
9
Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.在接受艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺治疗 144 周的 HIV-1 初治患者中罕见出现耐药性。
J Clin Virol. 2018 Jun;103:37-42. doi: 10.1016/j.jcv.2018.03.012. Epub 2018 Apr 2.
10
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.成人 HIV 和 M184V/I 突变患者换用艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺。
J Acquir Immune Defic Syndr. 2021 Apr 1;86(4):490-495. doi: 10.1097/QAI.0000000000002595.
引用本文的文献
1
Prevalence and factors associated with HIV viral rebound in individuals on ART: A systematic review study.接受抗逆转录病毒治疗的个体中HIV病毒反弹的患病率及相关因素：一项系统综述研究。
J Public Health Afr. 2025 Aug 15;16(1):1324. doi: 10.4102/jphia.v16i1.1324. eCollection 2025.
2
Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy-Update 2022: Systematic Review.接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者中药物相互作用的临床相关性——2022年更新：系统评价
Pharmaceutics. 2023 Oct 18;15(10):2488. doi: 10.3390/pharmaceutics15102488.
3
A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants.整合酶抑制剂（INSTIs）抗新兴和不断进化的耐药性 HIV-1 整合酶突变体的计算概述。
Arch Microbiol. 2023 Mar 26;205(4):142. doi: 10.1007/s00203-023-03461-8.
本文引用的文献
1
Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.在接受艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺治疗 144 周的 HIV-1 初治患者中罕见出现耐药性。
J Clin Virol. 2018 Jun;103:37-42. doi: 10.1016/j.jcv.2018.03.012. Epub 2018 Apr 2.
2
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.简要报告：替诺福韦艾拉酚胺（TAF）与富马酸替诺福韦二吡呋酯（TDF）分别与埃替拉韦、考比司他和恩曲他滨（E/C/F）联合用于初治HIV-1感染的随机、双盲比较：第144周结果
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350.
3
Inclusion of salt form on prescription medication labeling as a source of patient confusion: a pilot study.将盐类形式列入处方药标签导致患者困惑：一项试点研究。
Pharm Pract (Granada). 2016 Jan-Mar;14(1):677. doi: 10.18549/PharmPract.2016.01.677. Epub 2016 Mar 15.
4
Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.在接受埃替拉韦韦/考比司他/恩曲他滨/替诺福韦酯富马酸盐治疗的患者中，首次治疗失败时间点的早期耐药性发展分析。
J Antimicrob Chemother. 2015 Sep;70(9):2632-8. doi: 10.1093/jac/dkv149. Epub 2015 Jun 24.
5
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯、艾维雷韦、考比司他、恩曲他滨复方制剂，用于治疗人类免疫缺陷病毒 1 型感染的初始治疗：两项随机、双盲、III 期、非劣效性试验。
Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.
6
Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects.多替拉韦与矿物质补充剂联合给药在健康成年受试者中的药代动力学。
J Clin Pharmacol. 2015 May;55(5):490-6. doi: 10.1002/jcph.439. Epub 2014 Dec 30.
7
Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents.每日一次给予增效后的艾维雷韦联合抑酸剂时的药代动力学。
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):45-50. doi: 10.1097/QAI.0b013e31829ecd3b.
8
Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.HIV 整合酶抑制剂艾维雷格的临床药代动力学和药效学特征。
Clin Pharmacokinet. 2011 Apr;50(4):229-44. doi: 10.2165/11584570-000000000-00000.
9
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.抗酸剂对人类免疫缺陷病毒血清阴性志愿者利匹韦林药代动力学的影响。
Antimicrob Agents Chemother. 2010 Dec;54(12):4999-5003. doi: 10.1128/AAC.00636-10. Epub 2010 Oct 4.
Zotero 插件